PV

Padmanabhuni Venkatanaga Sanjay

Active Director Director DIN 00863595
DIN 00863595 First appointment Jan 1995 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 2 active board seats
Past companies 3 historical roles
Total affiliations 5 Since Jan 1995
Shareholding value •••• Premium profile

About Padmanabhuni Venkatanaga Sanjay

Data last updated:

Padmanabhuni Venkatanaga Sanjay is a Director at Meenaxy Pharma Private Limited (since 1995) and Director at Sai Med Pharma Systems Private Limited (since 1995). The companies operate in Pharma and Chemicals. The 2 current companies with reported revenue have a combined latest revenue of ₹34.47 Cr; the largest is Meenaxy Pharma Private Limited at ₹23.09 Cr (FY 2024). Earlier, Padmanabhuni Venkatanaga Sanjay was a Director at Sri Sadguru Dhanvantari Pharma Private Limited (2010–2018) and Director at Meenaxy Life Sciences Limited (from 2009) and 1 more.

DIN 00863595
Primary Designation Director
Industry Pharma
First Appointment 18 Jan 1995
Oldest Company Age 31 yrs
Largest company Meenaxy Pharma Private Limited · ₹23.09 Cr (FY 2024)
Combined revenue ₹34.47 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Meenaxy Pharma Private Limited U24239TG1995PTC022370
Director24 Nov 19951995₹23.09 Cr (FY 2024)Active
Director18 Jan 19951995₹11.38 Cr (FY 2024)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director02 Jun 20102010Under Process Of Striking Off
Meenaxy Life Sciences Limited U24100TG2009PLC063618
Director08 May 20092009Strike Off
Director18 Feb 20112011Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Padmanabhuni Venkatanaga Sanjay

Directorship timeline

Open interactive timeline →
Meenaxy Life Sciences Limited
Zenmax Pharmaceuticals Private Limited
Sai Med Pharma Systems Private Limited
Meenaxy Pharma Private Limited
Premium access

Shareholding and investment profile for Padmanabhuni Venkatanaga Sanjay

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Padmanabhuni Venkatanaga Sanjay

Padmanabhuni Venkatanaga Sanjay currently holds 2 directorships: Meenaxy Pharma Private Limited (Director, since 24 Nov 1995, revenue ₹23.09 Cr (FY 2024)); Sai Med Pharma Systems Private Limited (Director, since 18 Jan 1995, revenue ₹11.38 Cr (FY 2024)).

Padmanabhuni Venkatanaga Sanjay was first appointed on 18 Jan 1995 as Director at Sai Med Pharma Systems Private Limited. The most recent appointment on record is 18 Feb 2011 at Zenmax Pharmaceuticals Private Limited.

The 2 current companies of Padmanabhuni Venkatanaga Sanjay that report revenue have a combined latest revenue of ₹34.47 Cr: Meenaxy Pharma Private Limited ₹23.09 Cr (FY 2024); Sai Med Pharma Systems Private Limited ₹11.38 Cr (FY 2024).

Padmanabhuni Venkatanaga Sanjay held 3 earlier board appointments: Sri Sadguru Dhanvantari Pharma Private Limited (Director, 02 Jun 2010 to 20 Aug 2018); Meenaxy Life Sciences Limited (Director, from 08 May 2009); Zenmax Pharmaceuticals Private Limited (Director, from 18 Feb 2011).

The current boards of Padmanabhuni Venkatanaga Sanjay's companies include Anusha Kodali (Meenaxy Pharma Private Limited), Padmanabhuni Venkata Naga Amar (Meenaxy Pharma Private Limited), Raja Sulochana Kodali (Meenaxy Pharma Private Limited), Padmanabhuni Venkata Appaji (Sai Med Pharma Systems Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available